
Johnson & Johnson JNJ
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSESPB |
Shares |
2.41 B |
Market Cap[1] |
$ 656 B |
EBITDA (LTM) |
$ 7.5 B |
P/E (LTM) |
23.160827 |
P/S (LTM) |
6.588383 |
EPS (LTM) |
11.13 |
Johnson & Johnson is a multinational corporation that specializes in healthcare products, medical devices, and pharmaceuticals. Founded in 1886, the company has grown to become one of the largest healthcare companies in the world, with operations in over 60 countries.
The company's products are used by millions of people every day, from baby shampoo and band-aids to prescription drugs and surgical equipment. Some of its most well-known brands include Tylenol, Neutrogena, and Listerine.
Johnson & Johnson is committed to improving the health and well-being of people around the world. The company invests heavily in research and development, with a focus on finding new treatments for diseases such as cancer, Alzheimer's, and HIV/AIDS.
In addition to its healthcare products, Johnson & Johnson is also known for its commitment to corporate social responsibility. The company has a long history of supporting various charitable causes, including disaster relief efforts and global health initiatives.
Overall, is a trusted and respected leader in the healthcare industry, with a strong track record of innovation and social responsibility.
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
Reata Pharmaceuticals
RETA
|
- | - | $ 6.29 B | Nasdaq Global Market,SPB | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 119.1 | 2.14 % | $ 7.74 B | Nasdaq Global Market,SPB | ||
|
iTeos Therapeutics
ITOS
|
- | - | $ 411 M | Nasdaq Global Market | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 2.76 | -8.35 % | $ 36.8 M | Nasdaq Global Market | ||
|
PolarityTE
PTE
|
- | -0.82 % | $ 1.78 M | Nasdaq Capital Market | ||
|
Kronos Bio
KRON
|
- | 1.49 % | $ 50.8 M | Nasdaq Global Select Market | ||
|
Cullinan Management
CGEM
|
$ 9.01 | -2.86 % | $ 543 M | Nasdaq Global Select Market | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
$ 54.13 | 2.46 % | $ 151 M | Nasdaq Global Select Market | ||
|
Advaxis
ADXS
|
- | -9.65 % | $ 45.9 M | Nasdaq Capital Market | ||
|
Trevena
TRVN
|
- | -46.58 % | $ 31.8 M | Nasdaq Capital Market | ||
|
Calithera Biosciences
CALA
|
- | -10.95 % | $ 876 K | Nasdaq Global Select Market | ||
|
Molecular Templates
MTEM
|
- | -23.43 % | $ 495 K | Nasdaq Capital Market | ||
|
Oncorus
ONCR
|
- | -8.54 % | $ 3.19 M | Nasdaq Global Market | ||
|
BioXcel Therapeutics
BTAI
|
$ 0.07 | 9.81 % | $ 855 K | Nasdaq Global Select Market,SPB | ||
|
Novan
NOVN
|
- | -24.84 % | $ 2.64 M | Nasdaq Capital Market | ||
|
CohBar
CWBR
|
- | -15.44 % | $ 2.2 M | Nasdaq Capital Market | ||
|
NeuBase Therapeutics
NBSE
|
- | -1.56 % | $ 12.3 M | Nasdaq Global Select Market | ||
|
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | ||
|
Arena Pharmaceuticals
ARNA
|
- | -6.81 % | $ 3.04 B | Nasdaq Global Select Market,SPB | ||
|
Scopus BioPharma
SCPS
|
- | -48.37 % | $ 3.71 M | Nasdaq Global Select Market | ||
|
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market | ||
|
Annovis Bio
ANVS
|
$ 0.81 | 9.63 % | $ 16.6 M | NYSE American | ||
|
scPharmaceuticals
SCPH
|
- | - | $ 218 M | Nasdaq Global Select Market | ||
|
X4 Pharmaceuticals
XFOR
|
$ 3.02 | -2.27 % | $ 128 M | Nasdaq Capital Market | ||
|
Entasis Therapeutics Holdings
ETTX
|
- | - | $ 105 M | Nasdaq Global Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.52 | -0.62 % | $ 5.75 M | Nasdaq Capital Market | ||
|
Athersys
ATHX
|
- | 3.77 % | $ 22.4 M | Nasdaq Capital Market | ||
|
Global Blood Therapeutics
GBT
|
- | - | $ 4.62 B | Nasdaq Global Select Market,SPB | ||
|
Inozyme Pharma
INZY
|
- | - | $ 207 M | Nasdaq Global Select Market | ||
|
NanoString Technologies
NSTG
|
- | -37.43 % | $ 5.1 M | Nasdaq Global Select Market | ||
|
Evogene Ltd.
EVGN
|
$ 0.36 | 5.82 % | $ 2.83 M | Nasdaq Global Market | ||
|
Humanigen
HGEN
|
- | -81.12 % | $ 4.28 M | Nasdaq Global Select Market | ||
|
CNS Pharmaceuticals
CNSP
|
$ 4.44 | 6.99 % | $ 1.97 M | Nasdaq Capital Market | ||
|
Sorrento Therapeutics
SRNE
|
- | -29.58 % | $ 126 M | Nasdaq Global Select Market | ||
|
Surface Oncology
SURF
|
- | - | $ 59.7 M | Nasdaq Global Select Market | ||
|
Sierra Oncology
SRRA
|
- | -0.05 % | $ 1.34 B | Nasdaq Global Select Market | ||
|
Gilead Sciences
GILD
|
$ 168.96 | -0.77 % | $ 210 B | Nasdaq Global Select Market,SPB | ||
|
Vaccinex
VCNX
|
- | -61.37 % | $ 654 K | Nasdaq Global Select Market | ||
|
Nymox Pharmaceutical Corporation
NYMX
|
- | -19.68 % | $ 18.4 M | Nasdaq Capital Market | ||
|
Jounce Therapeutics
JNCE
|
- | - | $ 98.4 M | Nasdaq Global Select Market | ||
|
Cocrystal Pharma
COCP
|
$ 0.96 | -4.95 % | $ 10.8 M | Nasdaq Capital Market | ||
|
Fortress Biotech
FBIO
|
$ 1.89 | 3.85 % | $ 52.7 M | Nasdaq Capital Market | ||
|
Acorda Therapeutics
ACOR
|
- | -24.86 % | $ 820 K | Nasdaq Global Select Market | ||
|
Ampio Pharmaceuticals
AMPE
|
- | -11.43 % | $ 502 K | NYSE American | ||
|
Longeveron
LGVN
|
$ 1.93 | -8.53 % | $ 33.9 B | Nasdaq Global Select Market | ||
|
Mersana Therapeutics
MRSN
|
- | - | $ 3.56 B | Nasdaq Global Select Market | ||
|
Akari Therapeutics, Plc
AKTX
|
$ 6.51 | 14.22 % | $ 438 B | Nasdaq Capital Market | ||
|
CymaBay Therapeutics
CBAY
|
- | - | $ 3.45 B | Nasdaq Global Select Market | ||
|
Freeline Therapeutics Holdings plc
FRLN
|
- | - | $ 384 M | Nasdaq Global Select Market | ||
|
Allakos
ALLK
|
- | - | $ 28.6 M | Nasdaq Global Select Market,SPB |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.